If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

SSRI medications have come under scrutiny as of late, despite medical experts maintaining they're safe and effective.

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

In SYMPHONY, AXS-12 was well tolerated with no new safety signals, Thorpy said. The main adverse effects were gastrointestinal, including dry mouth, nausea, constipation, and decreased appetite. One ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

At the end of Week 6 of the randomized withdrawal period in Study 0170, norepinephrine reuptake inhibition with ampreloxetine resulted in a sustained improvement in orthostatic blood pressure ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...

Epinephrine (also called adrenaline) and norepinephrine (also called noradrenaline) have a lot in common. Both are hormones that travel through your body, affecting many tissues and organs.